Grifols, S.A. Class A
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jose Ignacio Abia Buenache
- Full Time Employees
- 25,258
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Parque Empresarial Can Sant Joan Barcelona CT Spain 08174
- IPO Date
- Jun 5, 2006
- Website
- grifols.com
- Similar Companies
- Business
- Grifols, S.A. (GRF.MC) is a global healthcare company specializing in the development, manufacturing, and distribution of plasma-derived medicines and biopharmaceuticals; it leads in transfusion medicine solutions, clinical diagnostics, and biological supplies for research and manufacturing. Founded in 1909 and headquartered in Sant Cugat del Vallès near Barcelona, Spain, the company operates over 400 plasma collection centers worldwide, including in North America, Europe, Africa, the Middle East, and China via its partnership with Shanghai RAAS, serving more than 110 countries with a workforce exceeding 23,000 employees. Its core products encompass plasma-derived therapies for immunology, infectious diseases, pulmonology, neurology, hematology, hepatology, and critical care, such as immunoglobulins (including Yimmugo for primary immunodeficiency, approved by the FDA in 2024 with U.S. launch planned for Q1 2025), antithrombin III (THROMBATE III with recent U.S. expanded pediatric indication), albumin solutions, and coagulation factors; transfusion medicine offerings include devices, reagents, and systems for blood safety; diagnostics feature in vitro testing instruments, software, and reagents; hospital products cover saline solutions, enteral nutrition, and medical devices for compounding and inventory; while bio supplies provide plasma, serum, and proteins for life sciences and IVD manufacturing. Recent developments include the June 2024 completion of a strategic alliance with Haier Group through the sale of a 20% stake in Shanghai RAAS, raising funds to bolster operations; rejection of a €6.45 billion takeover bid from Brookfield in November 2024; leadership changes with Nacho Abia as CEO in April 2024, Anne-Catherine Berner as Chair in June 2025, and Rahul Srinivasan as CFO in July 2024; debt restructuring via €1.3 billion secured notes and a €1 billion private placement in 2024-2025; delisting of subsidiary Biotest in June 2025; and strong financial performance with Q3 2025 revenues of €1.865 billion (up 7% H1 2025) and guidance for €10 billion revenue by 2029.
Company News
Grifols, S.A. (NASDAQ:GRFS) Sees Significant Increase in Short Interest
Head to Head Analysis: Creative Medical Technology (NASDAQ:CELZ) versus Grifols (NASDAQ:GRFS)
GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
Grifols says Canada plasma license suspension has no impact
Grifols: Better Plasma Economics Can Unlock A Discounted Equity
Analyzing Gilead Sciences (NASDAQ:GILD) & Grifols (NASDAQ:GRFS)
GRFS or SDZNY: Which Is the Better Value Stock Right Now?
Oakmark International Small Cap Strategy Q2 2026 Portfolio Update
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
Grifols, S.A. (GIKLY) Q2 2026 Earnings Call Transcript
Grifols Q2 Earnings Call Highlights
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst
Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript
Aldeyra Therapeutics (NASDAQ:ALDX) and Grifols (NASDAQ:GRFS) Head to Head Comparison
Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates
Grifols approves IPO of its US biopharma business
Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson's Disease